Alaska Ozempic (GLP-1) Lawsuit: The Litigation, Explained

Marin & Murphy

Ozempic (GLP-1) — Alaska Litigation

The Ozempic Litigation, Explained

Two consolidated federal proceedings, a September 2026 expert hearing, and state deadlines that vary — here is where the litigation stands.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Marin & Murphy is not licensed in Alaska; details below.

Partners

Matthew T. Marin & Stefanie A. Murphy

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Whether any individual has a claim depends on their medical records and the law of their state. The information below covers the litigation itself.

Distance defines Alaska litigation — and GLP-1 cases travel farther than most. A claim that begins in Anchorage or anywhere else in the state is consolidated 4,000 miles away: stomach-injury suits in MDL 3094, NAION vision-loss suits in MDL 3163, both before Judge Karen S. Marston in the Eastern District of Pennsylvania.

Marin & Murphy Law Firm is licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina, and is not licensed to practice law in Alaska. This page is provided for informational purposes and does not constitute an offer to represent any Alaska resident. The firm does not accept Alaska legal matters; inquiries from Alaska residents are referred to attorneys licensed in Alaska.

From the District of Alaska to Philadelphia

There is one federal court here — the U.S. District Court for the District of Alaska — and every GLP-1 injury case filed in it is subject to the same JPML transfer orders as the rest of the country: stomach injuries to MDL 3094, NAION to MDL 3163, both centralized before Judge Karen S. Marston in the Eastern District of Pennsylvania. As of the October 2026 JPML statistics, 4,025 cases were pending in MDL 3094 and 247 in MDL 3163, with no verdicts and no settlements anywhere in either docket.

An Alaska case, up close: the count it didn’t check

No official count breaks these dockets down by state, so we track actual Alaska filings from the record rather than guess. On January 27, 2026, an Alaska resident filed Yager v. Novo Nordisk, No. 2:26-cv-00530 (E.D. Pa.) — an 11-page short form complaint on the public docket, direct-filed into MDL 3094 with the District of Alaska designated as its Original Venue — the home court the case is set up to return to for trial, subject to the challenges the Direct Filing Order preserves. Direct filing let the case enter the MDL immediately, skipping the wait for a JPML transfer order, while still preserving that home district as its designated Original Venue if the case is later transferred out for trial.

The filing alleges Ozempic use from January to March 2024 and checks three injuries from the form’s list — gastroparesis, an esophageal blockage, and intestinal obstruction. It adopts eleven of the master complaint’s sixteen counts, led by the failure-to-warn core and running through negligent undertaking, but leaves Count X unchecked. That is not an oversight: the master complaint does not plead Alaska’s consumer-protection statute in that count, as its own state-law inventory reflects, and Alaska is not a product-liability-act state either — so the common-law counts carry the entire claim. Like every case in the MDL, it was deemed answered and denied the day it was filed, with no individual answer from Novo Nordisk ever appearing on the docket. The form’s fields are walked through on our short form complaint page.

The cautions that apply everywhere apply here: one plaintiff’s pleading, reproduced from the public record, its allegations unproven and disputed. No court has ruled on the merits of any GLP-1 injury claim in Alaska or elsewhere. What it checked and skipped is not a verdict on any other Alaskan’s claim. The deadline that governed this filing is covered next.

Two years, Alaska rules

Alaska pairs a two-year statutory period with accrual rules that turn on your medical timeline. What that produces for any individual claimant depends on dates — diagnosis, treatment, attribution — that only a case-specific review can pin down. The statutes are cited in the deadline section below.

Who may qualify

• Stomach injuries (gastroparesis or gastric obstruction): use of brand-name Ozempic, Wegovy, or Rybelsus (not compounded or generic semaglutide); a diagnosis confirmed by objective testing such as a gastric emptying study, made while taking the medication or within about 30 days of stopping; a related emergency-room visit or hospital admission; and a diagnosis made before December 31, 2024.
• NAION (sudden optic-nerve vision loss): use of brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound; an actual NAION diagnosis made during or after use; and some degree of permanent vision impairment.
• Criteria evolve, and near-miss situations are often worth reviewing with a lawyer licensed in your state.

Common questions

How widespread is GLP-1 use in Alaska?

For a state of Alaska’s size, the numbers are striking: over 24,000 GLP-1 prescriptions through Medicaid alone in 2024 (CMS data), the overwhelming majority of them Ozempic. CDC surveillance (2023) adds the context — 8.2% of Alaska adults with diagnosed diabetes, 35.3% with obesity — and commercial payers push actual statewide use well past the Medicaid floor.

Do Alaska Ozempic cases stay in Alaska?

No — and Alaska cases have the farthest to go. The JPML transfers GLP-1 suits from the District of Alaska to the consolidated dockets in Philadelphia (MDL 3094 for stomach injuries, MDL 3163 for NAION). A case still unresolved when pretrial work ends can be remanded home for trial.

GLP-1 prescribing across Alaska: the data

Ozempic dominates Alaska’s Medicaid GLP-1 prescribing: at least 19,280 prescriptions in 2024, with at least 1,699 more for Mounjaro and 1,698 for Trulicity, per CMS State Drug Utilization Data. Set against CDC 2023 age-adjusted rates — 8.2% adult diabetes, 35.3% obesity — the pattern tracks the state’s health profile. Counts are floors: one payer, suppressed small cells.

The controlling Alaska time limits

Alaska’s standard window for filing a personal-injury case is two years (Alaska Stat. § 09.10.070(a)), with a discovery rule in Alaska that starts the period when you knew or reasonably should have known of the injury and what caused it — and that is exactly why the date your gastroparesis or NAION was linked to a GLP-1 drug matters. A wrongful-death claim carries a two-year period that begins at death (Alaska Stat. § 09.55.580(a)), brought by the personal representative. Federal filings from Alaska move into the consolidated GLP-1 dockets for their pretrial phase. Exceptions exist on both sides of these rules — your actual deadline emerges only from a review of your own dates.

Nearby: Ozempic lawsuit information for Washington, Oregon, Idaho, Hawaii, California, and Nevada — or browse every state.